An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk

BRCA1 Mutation Clinical Trial

Official title: Digital Technology to Enhance Access to and Effectiveness of Cancer Genetic Counseling: Effective Familial OutReach Via Tele-genetics (EfFORT) Trial & Supporting Test Result Interpretation and Variant Education (STRIVE) Trial

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate a cascade genetic testing intervention. Cascade testing is the process of offering genetic testing to people who are at risk of having inherited a possibly harmful gene change that has been found in their family. This process is repeated as more people within the family are found to have the gene change. The study will look at how often genetic testing occurs when healthcare providers have permission to reach out to family members to recommend genetic testing and to help those who are interested get tested. The study will look at whether this cascade testing intervention is practical and effective. The study would like to see how this approach of healthcare providers reaching out directly to family members compares with the usual approach of patients telling their family members about the recommendation to get genetic testing.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Adenomatous Polyposis Coli
• ATM Gene Mutation
• BARD1 Gene Mutation
• BRCA1 Mutation
• BRCA2 Mutation
• BRIP1 Gene Mutation
• CHEK2 Gene Mutation
• MLH1 Gene Mutation
• MSH2 Gene Mutation
• MSH6 Gene Mutation
• PALB2 Gene Mutation
• PMS2 Gene Mutation
• POLD1 Gene Mutation
• POLE Gene Mutation
• PTEN Gene Mutation
• RAD51C Gene Mutation
• RAD51D Gene Mutation

• NCT number: NCT05420064
• Study type: Interventional
• Source: Memorial Sloan Kettering Cancer Center
• Contact: Kenneth Offit, MD, MPH
• Phone: 646-888-4059
• Email: offitk@mskcc.org
• Status: Recruiting
• Phase: N/A
• Start date: December 1, 2022
• Completion date: November 30, 2026